Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
This Can Predict Survival, Response to AML Chemo
Am J Hematol; ePub 2016 Aug 29; Short, et al
Day of blast disappearance (DOBD) >5 can be used as an indicator of chemosensitivity in people with acute myeloid leukemia (AML) who have poor prognosis, according to a retrospective analysis of 363 individuals.
Participants—all with untreated AML—had induction chemotherapy to determine the relationship between DOBD and complete remission, event-free survival, and overall survival. Among the results:
• DOBD ≤5 was best cutoff to determine overall survival.
• ~1 in every 10 patients had DOBD >5.
• Complete remission rate was 74% in patients with DOBD ≤5 vs 29% in those >5.
• Median event-free survival was 9.4 and 1.8 months, respectively.
• Overall survival was 17.1 and 5.8 months, respectively.
• DOBD >5 was independently linked with lower complete remission, and short event-free and overall survival.
Short N, Benton C, Chun-Chen H, et al. Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy. [Published online ahead of print August 29, 2016]. Am J Hematol. doi:10.1002/ajh.24500.